Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment
Jia Zhou(Janssen (United States)), Weirong Wang(Xi'an Jiaotong University), Arnob Banerjee(Johnson & Johnson (United States)), Alfredo Perales‐Puchalt(The Wistar Institute), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Katherine Chastain(Janssen (United States)), Nahor Haddish‐Berhane, Yue Guo(Janssen (United States)), Deeksha Vishwamitra(Janssen (United States)), Caroline Hodin(Janssen (Belgium)), Raluca Verona(Centre Hospitalier Universitaire de Nantes)
Cited by 0
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k